Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rupatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 18/20 | 0.86 |
| ▸ | PTAFR known ✓ | P25105 | 2/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | FNTA | P49354 | 3/20 | 0.60 |
| ▸ | FNTB | P49356 | 3/20 | 0.60 |
| ▸ | SLC6A15 | Q9H2J7 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rupatadine SCHEMBL19474963 | 1.00 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL31116805 | 1.00 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29101069 | 1.00 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL180512 | 1.00 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL180121 | 1.00 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL27743704 | 0.98 | HRH1 (0.82) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29400290 | 0.93 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL27703 | 0.93 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL30730975 | 0.93 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL28585002 | 0.92 | HRH1 (0.98) | HRH1PTAFRKCNH2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | TELIOS PHARMA INC. (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | TELIOS PHARMA INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | disclosed |
| US-12371708-B2 | Plants comprising wheat G-type cytoplasmic male sterility restorer genes, molecular markers and uses thereof | BASF SE (DE) | 2025-07-29 | — | — | US | disclosed |
| EP-3485022-B1 | PLANTS COMPRISING WHEAT G-TYPE CYTOPLASMIC MALE STERILITY RESTORER GENES, MOLECULAR MARKERS AND USES THEREOF | BASF SE (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2025057872-A1 | REGULATORY T CELL INDUCTION PROMOTER, THERAPEUTIC OR PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASE, THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISEASE, FOOD COMPOSITION FOR PREVENTING AUTOIMMUNE DISEASE, FOOD COMPOSITION FOR PREVENTING ALLERGIC DISEASE, FOOD COMPOSITION FOR IMPROVING ALLERGIC STATE, FOOD COMPOSITION FOR MAINTAINING HEALTHY IMMUNE FUNCTION, METHOD FOR TREATING OR PREVENTING AUTOIMMUNE DISEASE OR ALLERGIC DISEASE, AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF PROMOTING INDUCTION OF REGULATORY T CELL | 学校法人藤田学園 | 2025-03-20 | — | — | WO | disclosed |
| EP-3397285-B1 | TABLET FORMULATIONS OF MONTELUKAST SODIUM AND RUPATADINE FUMARATE | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2024-08-14 | — | — | EP | disclosed |
| EP-3397285-B1 | TABLET FORMULATIONS OF MONTELUKAST SODIUM AND RUPATADINE FUMARATE | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024126772-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH, S.A. (ES) | 2024-06-20 | — | — | WO | disclosed |
| US-11913011-B2 | Plants comprising wheat g-type cytoplasmic male sterility restorer genes and uses thereof | BASF SE (DE) | 2024-02-27 | — | — | US | disclosed |
| EP-4236949-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116496254-A | Preparation method of rupatadine fumarate | 南京海鲸药业股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112513305-B | Grain-oriented electromagnetic steel sheet | 日本制铁株式会社 | 2022-07-15 | — | — | CN | disclosed |
| CN-112469840-B | Grain-oriented electromagnetic steel sheet | 日本制铁株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022094422-A9 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| CN-112513306-B | Grain-oriented electromagnetic steel sheet | 日本制铁株式会社 | 2022-05-24 | — | — | CN | disclosed |
| WO-2022094422-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041685-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, KIT, LYN | HRH1 1366/4885PTAFR 2131/4885KCNH2 2448/4885 |
| US-12414950-B1 | Methods of treating indolent systemic mastocytosis | BTK, LYN, ABL1 | HRH1 679/4885PTAFR 1717/4885KCNH2 3183/4885 |
| US-20250360130-A1 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | BTK, LYN, ABL1 | HRH1 679/4885PTAFR 1717/4885KCNH2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.